CytoSorbents Selected to Present at Special Operations SOMSA 2017 Conference and 18th Annual B. Riley & Co. Investor Conference

MONMOUTH JUNCTION, N.J., May 24, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its CEO and CFO were selected to speak at two separate conferences later today. 

2017 Special Operations Medical Association Scientific Assembly (SOMSA)
Presenter: Dr. Phillip Chan MD, PhD, CEO
Talk:  "Development of New Treatments for Severe Hyperkalemia in Austere Conditions
Where:  Charlotte Convention Center, Charlotte, North Carolina
When:    Wednesday, May 24, 2017 at 1:45 PM PDT
Presentation Room:   207CD

Dr. Chan was invited to speak on the development of new potassium lowering technologies that utilize novel potassium-binding sorbents to treat severe hyperkalemia, a potentially life-threatening elevation of potassium in the blood that can occur as a result of severe trauma, burn injury, and tissue ischemia.  These strategies were specifically designed to be used to stabilize our wounded warfighters in austere battlefield environments, where delays in evacuation necessitate prolonged field care for up to 72 hours before they can be brought to definitive care.  U.S. Special Operations Command (SOCOM) synchronizes the planning of Special Operations and provides Special Operations Forces to support persistent, networked, and distributed Global Combatant Command operations in order to protect and advance our Nation's interests.  This work was funded through two Small Business Innovation Research (SBIR) contracts by the U.S. Army Medical Research and Materiel Command (USAMRMC). 

18^th Annual B. Riley & Co. Investor Conference
Presenter: Kathleen Bloch, CFO
Where:  Loews Santa Monica Beach Hotel, 1700 Ocean Avenue, Santa Monica, CA
When:    Wednesday, May 24, 2017 at 3:00PM PDT
Presentation Room:   Arcadia D

Ms. Bloch will be meeting with investors in one-on-one meetings during the two day conference (May 24-25^th).  A copy of the presentation will be available on the company's investor relations website.

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 43 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorbents has completed its REFRESH (REduction in FREe Hemoglobin) 1 trial – a multi-center, randomized controlled study that has demonstrated the safety and efficacy of free hemoglobin reduction with intra-operative CytoSorb® use in a heart-lung machine during complex cardiac surgery.  In 2017, the company plans to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA approval.  CytoSorb® has been used safely in more than 23,000 human treatments to date.

CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding in excess of $18 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including CytoSorb-XL, HemoDefend™, VetResQ™, ContrastSorb, DrugSorb, and others.  For more information, please visit the Company's websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 3, 2017, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws. 

Please Click to Follow Us on Facebook and Twitter

Cytosorbents Contact:
Amy Vogel
Investor Relations
(732) 398-5394
[email protected]

Public Relations Contact:
Amy Phillips     
Pascale Communications     
412-327-9499     
[email protected] 

SOURCE CytoSorbents Corporation